Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego
26 Oct 2018
Alderley Park, 26 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, is pleased to announce that the Company has presented a poster, entitled ‘ROCK2 inhibitors for the treatment of chronic kidney disease’ at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA, on 25 October 2018.
This first disclosure of the Redx ROCK2 selective inhibitor programme describes a series of potent and highly selective ROCK2 inhibitors that potently suppress the release of pro-fibrotic factors from kidney mesangial cells. In an in vivo model of acute kidney injury, the Redx selective ROCK2 tool compound reduced podocyte damage and the expression of inflammatory and profibrotic genes in the kidney. In addition, a telemetered rat study indicated that the Redx selective ROCK2 inhibitor avoids the cardiovascular side-effects typically observed with systemic pan-ROCK inhibitors.
Redx believe that their highly selective ROCK2 inhibitors could provide a novel and effective therapy for patients with progressive kidney fibrosis associated with diabetes, who currently have few, largely ineffective, therapeutic options.
Richard Armer, Chief Scientific Officer commented: “We are pleased that our poster was presented at the high profile American Society of Nephrology Kidney Week. We believe our highly selective ROCK2 inhibitors have the potential to be best-in-class agents for the treatment of fibrotic diseases of the kidney such as diabetic nephropathy (DN) and of the liver such as non-alcoholic steatohepatitis (NASH). This is the first publication of our ROCK2 project data and we are delighted that the high quality of our research has been recognised by the ASN.”
The poster, entitled ‘ROCK2 inhibitors for the treatment of chronic kidney disease’ presented at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA, on 25 October 2018, can be accessed here:
For further information, please contact:
|Redx Pharma Plc||T: +44 1625 469 920|
|Lisa Anson, Chief Executive Officer
Andrew Saunders, Chief Medical Officer
|Cantor Fitzgerald Europe (Nominated Advisor & Broker)||T: +44 20 7894 7000|
|WG Partners LLP (Joint Broker)||T: +44 20 3705 9330|
|Claes Spång/ Chris Lee/ David Wilson|
|FTI Consulting||T: +44 20 3727 1000|
|Simon Conway/Stephanie Cuthbert|
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/